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Abstract
Cancer-related fractures of the spine are different from osteopo-
rotic ones, not only in pathogenesis but also in natural history and 
treatment. Higher class evidence now supports offering balloon 
kyphoplasty to a patient with cancer, provided that the pain is sig-
nificant in intensity, has a positional character, and correlates to 
the area of the fractured vertebrae. Absence of clinical spinal cord 
compression and overt instability are paramount. Because of the 
frequent disruption of the posterior vertebral body cortex in these 
patients, the procedure should be performed by experienced oper-
ators who could also quickly perform an open decompression if ce-
ment extravasation occurs. Patients will benefit from vertebral aug-
mentation, even in chronic malignant fractures. A biopsy should be 
routinely performed and a combination with radiation treatment 
would be beneficial in most cases. (JNCCN 2012;10:715–719)
arm prospective studies have reported good results with 
VP, and especially BKP.1–8 However, results of the first 
randomized trial (Cancer Fracture Evaluation [CAFE] 
study) are now available, which show the superiority 
of immediate BKP compared with nonsurgical man-
agement.9 This prospective, randomized, multicenter 
study involved 134 patients assigned either to kypho-
plasty (n = 70) or as controls (n = 64). The results of 
the CAFE study strongly favor kyphoplasty in terms of 
pain and disability reduction, improvement in quality 
of life, and decrease in analgesic use. More than half of 
the patients in the control group (n = 38) crossed over 
to the kyphoplasty group after the 1-month assessment, 
with similar outcomes as those seen in the original ky-
phoplasty group. 
VAPs have many advantages, including immediate 
impact, reduced mortality,10 avoidance of deleterious ef-
fects of prolonged recumbency, more cost-effectiveness 
compared with conservative management,11 minimally 
invasive nature requiring outpatient care in most cases, 
biopsy, restoration of vertebral height,12 and potential 
antitumor effect of methylmethacrylate monomer and 
the heat generated by its polymerization.13 In selected 
cases, VAPs can also be combined with radiofrequen-
cy ablation to achieve better local tumor control.13,14 
Rare complications of VAPs include cement leakage 
to canal/foramen,15 pulmonary embolism,16 osteomyeli-
tis,17 pneumothorax, and retroperitoneal haematoma.1 
Most studies report higher rates of cement leakage with 
VP15,18 and better kyphosis reduction with BKP,12,19 
whereas BKP is more expensive. 
Because of the randomized trials that showed no 
benefit of VP compared with a sham procedure17,20 or 
conservative management,21 the value of VP in treating 
osteoporotic vertebral fractures has been questioned. 
Therefore, the American Academy of Orthopedic 
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Almost 3 years ago, the International Myeloma Work-
ing Group published a statement and raised some ques-
tions regarding the treatment of cancer-related fractures 
with vertebral augmentation procedures (VAPs). Some 
of those issues included indications, patient selection, 
preferred procedure (balloon kyphoplasty [BKP] vs. 
vertebroplasty [VP]), optimal intervention time, and 
alternatives.1
Among patients with cancer with vertebral com-
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Surgeons published guidelines against using VP in 
osteoporotic fractures.22 Furthermore, a retrospec-
tive analysis in a wide Medicare population claimed 
that BKP reduced mortality significantly more than 
nonsurgical management and VP.23 In the cancer 
population, both procedures have been regarded as 
effective, with only one nonrandomized study re-
porting better results at 6 months and 1 year with 
BKP versus VP in patients with myeloma.5 The ran-
domized CAFE trial now provides strong evidence 
for the superiority of BKP versus nonsurgical man-
agement; no randomized studies of VP in the cancer 
setting nor randomized controlled trials comparing 
VP with BKP have been published. For the reasons 
mentioned (more cement leakage with VP, better re-
duction of kyphosis/mortality benefit from BKP, and 
lack of randomized controlled trials supporting VP in 
patients with cancer), the authors favor BKP, espe-
cially in patients with significantly collapsed verte-
brae5 or fractures in high stress areas, such as the tho-
racolumbar junction.9 However, they do perform VP 
for nonindex fractures or nondeformed vertebrae to 
avoid unnecessary cost, but ultimately this is largely 
operator-dependent. 
The optimal time of VAPs is still debated. Al-
though in the osteoporotic population earlier inter-
vention may yield superior results16,17,24–26 and most 
authorities advocate a 6- to 8-week conservative 
trial in mild cases27 because recovery is anticipated 
with time, this may not be the case in malignant 
fractures. Patients with cancer have a less favorable 
natural course because of the increased rate of bone 
loss from tumor osteolysis, chemotherapy, radiation 
therapy (RT), gonadal ablation, compromised medi-
cal status, poor nutrition, generalized osteoporosis, 
and chronic steroid use. Additionally, they are less 
amenable to conservative treatment and prolonged 
immobilization, have limited expected survival, 
and their overall poor functional status interferes 
with the ability to administer other antineoplastic 
therapies. Therefore, a VAP should be offered to any 
patient who presents with significant pain (visual 
analog scale ≥ 4) that corresponds with the clinical 
examination and correlates with positive findings 
on MRI (edema on short-tau inversion recovery im-
ages). In older fractures, the improvement from BKP 
intervention may still be satisfactory.28 In fact, in the 
cancer fracture literature, most of the procedures 
were performed on subacute or chronic fractures.3,4,7–9 
In the CAFE trial, the patients who crossed over 
from nonsurgical management to undergo BKP after 
1 month reported comparable results to those who 
were initially randomized to BKP, indicating that 
BKP is still beneficial in older fractures.9 
Experience has taught that some of the con-
traindications reported previously17,29 now appear 
relative, such as canal encroachment,30,31 and upper 
thoracic31 or even cervical32 location of the fracture. 
With attention to detail and the advent of accessory 
tools, such as neuromonitoring and individualized 
techniques, indications are expanding and surgeons 
are challenging traditional notions that have previ-
ously deterred surgeons from using BKP in certain 
situations. Part of the reason is that these patients 
frequently cannot medically withstand the rigors of 
an open vertebrectomy. 
Vertebral height restoration is another factor fa-
voring VAPs. Theoretically it should prevent a dom-
ino effect through reducing overall kyphosis. In the 
CAFE study, rates of subsequent nonindex VCF in 
kyphoplasty and control groups were similar, despite 
significant restoration of vertebral height.9  
A biopsy of the affected vertebrae should be per-
formed concurrently with these procedures. The re-
sults may provide significant information regarding fu-
ture treatment, confirm the presence of metastasis, or 
reveal a new neoplasm, while not adding to the mor-
bidity of the operation.33 In fact, patients with cancer 
may develop VCFs because of a variety of causes, such 
as osteoporosis, prolonged steroid use, chemotherapy, 
or RT. Therefore, verification of metastasis provided 
by biopsy is not only important for staging purposes 
but may also preclude the use of additional treatments, 
such as RT. In a recent institutional review, only 50% 
of patients with cancer with VCFs had biopsy results 
showing malignant disease.8 A biopsy is also of para-
mount importance in cases of multiple primaries or 
when the VCF represents the first sign of metastasis 
after a long latency period.33–35
The number of levels that may be safely per-
formed in each session has not been defined; most 
authorities feel that up to 3 (or 4) levels may be 
safely performed without significantly increasing the 
length or morbidity of the operation.1,8,9 The authors 
frequently perform VAPs for impending or interven-
ing vertebrae, especially when kyphosis is present or 
if cement extravasation occurs in the disk space (in-
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Finally, regarding the relation of VAPs to RT, the 
authors believe they are complimentary treatments; 
although cement augmentation may exert a tumori-
cidal effect (toxic monomer and heat), the issue of 
effectively treating the underlying tumor cells within 
the vertebrae remains.37 Therefore, RT should be of-
fered to some of these patients. However, RT alone 
may be insufficient to control the pain and will not 
address painful mechanical instability.37 In fact, RT 
is known to produce detrimental bone effects, in-
cluding damage to the cellular and vascular bony 
elements and alteration of biomechanical proper-
ties in doses of 20 to 30 Gy.38,39 Rose et al.40 found 
a 39% chance of fracture after intensity-modulated 
RT for spinal metastasis. A combination of BKP and 
intensity-modulated RT may be a new treatment 
paradigm for some patients with malignant disease 
in the fractured vertebral body.41 However, the se-
quence must be determined and made on an indi-
vidualized basis, because no studies delineating this 
issue are currently available. Oncologists must weigh 
the potential benefits against the deleterious effects 
of RT to the affected vertebral body and adjacent or-
gans and, importantly, bone marrow function, which 
may compromise the ability to administer more im-
portant systemic therapeutic modalities required to 
treat patients with metastatic cancer or multiple 
myeloma.
In conclusion, cancer-related fractures of the 
spine are different from osteoporotic ones, not only 
in pathogenesis but also in natural history and treat-
ment. Class 1 to 2 evidence now supports offering a 
VAP to a patient with cancer, provided that the pain 
is significant in intensity, has a positional character 
(i.e., increases with axial loading), and correlates to 
the area of the fractured vertebrae. Patients will ben-
efit from vertebral augmentation, even in chronic 
malignant fractures.4,6,9 Figure 1 provides a proposed 
therapeutic algorithm for those fractures. Absence of 
clinical spinal cord compression and overt instability 
are paramount. Because of the frequent disruption of 
the posterior vertebral body cortex in these patients, 
the procedure should be performed by experienced 
operators who could also quickly perform an open 
decompression if cement extravasation occurs, or 
else a spine surgeon should be available in case com-
plications occur. A biopsy should routinely be per-
formed and a combination with RT would be benefi-
Spinal pain in a patient with 
history of cancer
MRI - tumor
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Figure 1 Algorithm for treatment of vertebral compression fractures.  
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cial in most cases. Given the improvement in quality 
of life that this minimally invasive procedure offers 
to patients with cancer, it should be considered and 
discussed, when appropriate, in lieu of open maxi-
mally invasive surgeries or pain ablation procedures.
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